'Acceptable' risk of drug treatment

Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study.

Scottish medical journal·2012

C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis.

Rheumatology (Oxford, England)·2008

Bone health in patients with fibromyalgia.

Rheumatology (Oxford, England)·2003

Rheumatoid arthritis and macrovascular disease.

Rheumatology (Oxford, England)·2003

A non-infective cause of recurrent purulent arthritis.

Scandinavian journal of rheumatology·2002

The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years' follow-up.

Clinical rheumatology·2002

A Phase 1 study of subcutaneous toripalimab in recurrent or metastatic nasopharyngeal carcinoma.

British journal of clinical pharmacology·2026

Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy.

British journal of clinical pharmacology·2026

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model-based simulation of the positioning imatinib for pulmonary arterial hypertension trial.

British journal of clinical pharmacology·2026

Medicines, misinformation and machines: Navigating infodemics in the generative AI era.

British journal of clinical pharmacology·2026

Indications for the treatment of primary hyperparathyroidism.

Journal of visceral surgery·2026

Sodium valproate at concentrations bracketing estimated seminal plasma levels impairs human sperm function in vitro through oxidative stress and mitochondrial dysfunction.

Toxicology·2026

Pharmacokinetics of repeated, high-dose fentanyl administration in rats.

Drug metabolism and disposition: the biological fate of chemicals·2026

A landscape analysis of Japanese tolerability assessments in oncology drug development.

Cancer treatment and research communications·2026

Opioid and Stimulant Coprescriptions among South Carolina Residents.

Southern medical journal·2026

Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease.

JAMA network open·2026

Related Experiment Videos

'Acceptable' risk of drug treatment

Related Concept Videos

Rosuvastatin might have an effect on C-reactive protein but not on rheumatoid disease activity: Tayside randomized controlled study.

C-reactive protein: the underlying cause of microvascular dysfunction in rheumatoid arthritis.

Bone health in patients with fibromyalgia.

Rheumatoid arthritis and macrovascular disease.

A non-infective cause of recurrent purulent arthritis.

The prevalence and significance of positive antinuclear antibodies in patients with fibromyalgia syndrome: 2-4 years' follow-up.

A Phase 1 study of subcutaneous toripalimab in recurrent or metastatic nasopharyngeal carcinoma.

Comparing outcomes using low-dose apixaban and anti-Xa monitoring and vitamin K antagonists in patients with renal replacement therapy.

Adaptive imatinib regimens can mitigate cumulative toxicity while sustaining hemodynamic benefit: A model-based simulation of the positioning imatinib for pulmonary arterial hypertension trial.

Medicines, misinformation and machines: Navigating infodemics in the generative AI era.

Indications for the treatment of primary hyperparathyroidism.

Sodium valproate at concentrations bracketing estimated seminal plasma levels impairs human sperm function in vitro through oxidative stress and mitochondrial dysfunction.

Pharmacokinetics of repeated, high-dose fentanyl administration in rats.

A landscape analysis of Japanese tolerability assessments in oncology drug development.

Opioid and Stimulant Coprescriptions among South Carolina Residents.

Opioid Dispensing Volume and Per-Patient Intensity in Sickle Cell Disease.

Related Experiment Videos

'Acceptable' risk of drug treatment

Related Concept Videos

Related Articles